An RNA-based system to study hepatitis B virus replication and evaluate antivirals

Yingpu Yu, William M. Schneider*, Maximilian A. Kass, Eleftherios Michailidis, Ashley Acevedo, Ana L. Pamplona Mosimann, Juliano Bordignon, Alexander Koenig, Christine M. Livingston, Hardeep van Gijzel, Yi Ni, Pradeep M. Ambrose, Catherine A. Freije, Mengyin Zhang, Chenhui Zou, Mohammad Kabbani, Corrine Quirk, Cyprien Jahan, Xianfang Wu, Stephan UrbanShihyun You, Amir Shlomai, Ype P. de Jong, Charles M. Rice*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Hepatitis B virus (HBV) chronically infects an estimated 300 million people, and standard treatments are rarely curative. Infection increases the risk of liver cirrhosis and hepatocellular carcinoma, and consequently, nearly 1 million people die each year from chronic hepatitis B. Tools and approaches that bring insights into HBV biology and facilitate the discovery and evaluation of antiviral drugs are in demand. Here, we describe a method to initiate the replication of HBV, a DNA virus, using synthetic RNA. This approach eliminates contaminating background signals from input virus or plasmid DNA that plagues existing systems and can be used to study multiple stages of HBV replication. We further demonstrate that this method can be uniquely applied to identify sequence variants that confer resistance to antiviral drugs.

Original languageEnglish
Article numbereadg6265
JournalScience advances
Issue number15
StatePublished - Apr 2023
Externally publishedYes


Dive into the research topics of 'An RNA-based system to study hepatitis B virus replication and evaluate antivirals'. Together they form a unique fingerprint.

Cite this